<p>Fennec Pharmaceuticals（納斯達克代碼：FENC - 獲取免費報告）的股票在週一的研究報告中被 Wedbush 的股票分析師重新給予了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 13.00 美元。Wedbush 的目標價顯示出相較於公司之前收盤價 112.77% 的潛在上漲空間。</p>
<p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾位分析師也對 FENC 發佈了報告。HC Wainwright 在 12 月 17 日的研究報告中重申了對 Fennec Pharmaceuticals 的 “買入” 評級，並給出了 13.00 美元的目標價。Stephens 在 11 月 18 日的研究報告中將 Fennec Pharmaceuticals 的評級上調至 “強力買入”。</p>
<p><strong>查看我們對 Fennec Pharmaceuticals 的最新股票分析</strong></p>
<h2>Fennec Pharmaceuticals 股票表現</h2>
<p>週一，納斯達克代碼：FENC 的股票下跌 0.77 美元，報 6.11 美元。該股票的交易量為 187,467 股，而其平均交易量為 111,607 股。Fennec Pharmaceuticals 的 1 年最低價為 3.96 美元，1 年最高價為 11.49 美元。該公司的 50 日簡單移動平均線為 6.39 美元，200 日簡單移動平均線為 5.61 美元。該股票的市值為 1.684 億美元，市盈率為-61.09，貝塔值為 0.36。</p>
<p>Fennec Pharmaceuticals（納斯達克代碼：FENC - 獲取免費報告）最後一次公佈財報是在 3 月 10 日。該公司報告本季度每股收益（EPS）為-0.06 美元，低於市場共識預期的 0.56 美元，差距為 0.62 美元。Fennec Pharmaceuticals 的淨利潤率為-2.30%，股本回報率為-53.38%。股票研究分析師預測 Fennec Pharmaceuticals 在當前年度將發佈-0.11 美元的每股收益。</p>
<h2>內部人士下注</h2>
<p>在相關消息中，董事 Rosty Raykov 在 3 月 5 日的交易中出售了 10,000 股公司的股票。該股票以平均價格 6.79 美元出售，總價值為 67,900.00 美元。交易完成後，該董事現在直接持有 68,725 股公司股票，價值約為 466,642.75 美元。此次交易使其持股減少了 12.70%。該出售在與證券交易委員會的法律文件中披露，該文件可通過 SEC 網站訪問。內部人士在上個季度共出售了 31,186 股公司股票，價值 203,389 美元。公司內部人士持有公司股票的 10.98%。</p>
<h2>機構投資者對 Fennec Pharmaceuticals 的看法</h2>
<p>最近幾家對沖基金增加或減少了對 FENC 的持股。Pinnacle Wealth Planning Services Inc.在第四季度購買了 Fennec Pharmaceuticals 的新股份，價值 97,000 美元。美國銀行在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 32.1%。美國銀行現在持有 35,827 股公司股票，價值 226,000 美元，此前在該期間又購買了 8,703 股。法國巴黎銀行金融市場在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 11.5%。法國巴黎銀行金融市場現在持有 44,626 股公司股票，價值 282,000 美元，此前在該期間又購買了 4,610 股。Solas Capital Management LLC 在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 17.0%。Solas Capital Management LLC 現在持有 2,250,919 股公司股票，價值 14,226,000 美元，此前在上個季度又購買了 327,383 股。最後，MetLife Investment Management LLC 在第四季度購買了 Fennec Pharmaceuticals 的新股份，價值約 99,000 美元。機構投資者持有公司股票的 55.51%。</p>
<h2>關於 Fennec Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Fennec Pharmaceuticals Inc 是一家生物製藥公司，開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防兒童順鉑引起的聽力損失或耳毒性的第三階段臨牀試驗。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Fennec Pharmaceuticals 更好</li>
<li>股票交易術語 - 每位投資者都需要了解的股票術語</li>
<li>當通貨膨脹上升時如何保護您的投資組合</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Fennec Pharmaceuticals 嗎？</h2>
<p>在您考慮 Fennec Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買...而 Fennec Pharmaceuticals 並不在名單上。</p>
<p>雖然 Fennec Pharmaceuticals 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

FENC

<p>Wedbush 重申了對 Fennec Pharmaceuticals（NASDAQ:FENC）的 “跑贏大盤” 評級，目標價為 13.00 美元，意味着相較於其前一交易日收盤價有 112.77% 的潛在上漲空間。該股票交易價格下跌至 6.11 美元，市值為 1.684 億美元。分析師預測當前年度每股收益為-0.11。機構投資者持有該公司 55.51% 的股份，最近的內部交易顯示董事 Rosty Raykov 的持股有所減少。Fennec Pharmaceuticals 專注於開發癌症治療方案，其主要候選藥物旨在預防兒童聽力損失</p>

<p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by stock analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $13.00 price objective on the stock. Wedbush's target price points to a potential upside of 112.77% from the company's previous close.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（納斯達克代碼：FENC - 獲取免費報告）的股票在週一的研究報告中被 Wedbush 的股票分析師重新給予了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 13.00 美元。Wedbush 的目標價顯示出相較於公司之前收盤價 112.77% 的潛在上漲空間。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other analysts have also issued reports on FENC. HC Wainwright restated a &#34;buy&#34; rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Stephens upgraded Fennec Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Monday, November 18th.</p>
<div class="lb-trans"><p>其他幾位分析師也對 FENC 發佈了報告。HC Wainwright 在 12 月 17 日的研究報告中重申了對 Fennec Pharmaceuticals 的 “買入” 評級，並給出了 13.00 美元的目標價。Stephens 在 11 月 18 日的研究報告中將 Fennec Pharmaceuticals 的評級上調至 “強力買入”。</p>
</div><p><strong>View Our Latest Stock Analysis on Fennec Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Fennec Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Fennec Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股票表現</h2>
</div><p>NASDAQ:FENC traded down $0.77 on Monday, hitting $6.11. The stock had a trading volume of 187,467 shares, compared to its average volume of 111,607. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $11.49. The firm's fifty day simple moving average is $6.39 and its two-hundred day simple moving average is $5.61. The stock has a market cap of $168.40 million, a P/E ratio of -61.09 and a beta of 0.36.</p>
<div class="lb-trans"><p>週一，納斯達克代碼：FENC 的股票下跌 0.77 美元，報 6.11 美元。該股票的交易量為 187,467 股，而其平均交易量為 111,607 股。Fennec Pharmaceuticals 的 1 年最低價為 3.96 美元，1 年最高價為 11.49 美元。該公司的 50 日簡單移動平均線為 6.39 美元，200 日簡單移動平均線為 5.61 美元。該股票的市值為 1.684 億美元，市盈率為-61.09，貝塔值為 0.36。</p>
</div><p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.62). Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. Equities research analysts predict that Fennec Pharmaceuticals will post -0.11 EPS for the current year.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（納斯達克代碼：FENC - 獲取免費報告）最後一次公佈財報是在 3 月 10 日。該公司報告本季度每股收益（EPS）為-0.06 美元，低於市場共識預期的 0.56 美元，差距為 0.62 美元。Fennec Pharmaceuticals 的淨利潤率為-2.30%，股本回報率為-53.38%。股票研究分析師預測 Fennec Pharmaceuticals 在當前年度將發佈-0.11 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In related news, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the completion of the transaction, the director now directly owns 68,725 shares in the company, valued at approximately $466,642.75. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 31,186 shares of company stock valued at $203,389 in the last quarter. Corporate insiders own 10.98% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Rosty Raykov 在 3 月 5 日的交易中出售了 10,000 股公司的股票。該股票以平均價格 6.79 美元出售，總價值為 67,900.00 美元。交易完成後，該董事現在直接持有 68,725 股公司股票，價值約為 466,642.75 美元。此次交易使其持股減少了 12.70%。該出售在與證券交易委員會的法律文件中披露，該文件可通過 SEC 網站訪問。內部人士在上個季度共出售了 31,186 股公司股票，價值 203,389 美元。公司內部人士持有公司股票的 10.98%。</p>
</div><h2>Institutional Investors Weigh In On Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Fennec Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in FENC. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Fennec Pharmaceuticals in the 4th quarter valued at $97,000. Bank of America Corp DE boosted its position in Fennec Pharmaceuticals by 32.1% during the fourth quarter. Bank of America Corp DE now owns 35,827 shares of the company's stock valued at $226,000 after buying an additional 8,703 shares during the period. BNP Paribas Financial Markets boosted its position in Fennec Pharmaceuticals by 11.5% during the fourth quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company's stock valued at $282,000 after buying an additional 4,610 shares during the period. Solas Capital Management LLC grew its stake in shares of Fennec Pharmaceuticals by 17.0% during the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock valued at $14,226,000 after buying an additional 327,383 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new position in shares of Fennec Pharmaceuticals in the fourth quarter worth about $99,000. Institutional investors own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>最近幾家對沖基金增加或減少了對 FENC 的持股。Pinnacle Wealth Planning Services Inc.在第四季度購買了 Fennec Pharmaceuticals 的新股份，價值 97,000 美元。美國銀行在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 32.1%。美國銀行現在持有 35,827 股公司股票，價值 226,000 美元，此前在該期間又購買了 8,703 股。法國巴黎銀行金融市場在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 11.5%。法國巴黎銀行金融市場現在持有 44,626 股公司股票，價值 282,000 美元，此前在該期間又購買了 4,610 股。Solas Capital Management LLC 在第四季度將其在 Fennec Pharmaceuticals 的持股增加了 17.0%。Solas Capital Management LLC 現在持有 2,250,919 股公司股票，價值 14,226,000 美元，此前在上個季度又購買了 327,383 股。最後，MetLife Investment Management LLC 在第四季度購買了 Fennec Pharmaceuticals 的新股份，價值約 99,000 美元。機構投資者持有公司股票的 55.51%。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家生物製藥公司，開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防兒童順鉑引起的聽力損失或耳毒性的第三階段臨牀試驗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Fennec Pharmaceuticals 更好</li>
<li>股票交易術語 - 每位投資者都需要了解的股票術語</li>
<li>當通貨膨脹上升時如何保護您的投資組合</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Fennec Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Fennec Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買...而 Fennec Pharmaceuticals 並不在名單上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Fennec Pharmaceuticals 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Fennec Pharmaceuticals (NASDAQ:FENC) 獲得了 Wedbush 的優於大盤評級